Lupus & antiphospholipid syndrome
Comparison of obinutuzumab and rituximab for treating neuropsychiatric lupus: a retrospective case-control study
Main finding · Complete or partial responseResult — go to the resultOdds ratio 3.08 95% CI 0.30–31.33Authors' conclusion
These findings suggest OBZ may induce superior clinical responses in NPSLE through enhanced B cell depletion, with acceptable safety at 12 months
Study context
- Population
- Patients with new-onset Neuropsychiatric SLE (NPSLE) meeting BILAG grade A criteria, treated 2018–2024 at Renji Hospital, Shanghai, with ≥12 months follow-up
- Participants
- 27 patients
- Comparison
- Obinutuzumab vs rituximab
- Obinutuzumab (OBZ)n = 9
- Rituximab (RTX)n = 18reference
- Outcome
- Complete or partial response
- Follow-up
- 12 months
Methodological detailspropensity score matched (1:2) on age, sex and SLEDAI, single-centre
- Propensity score matched (1:2) on age, sex and SLEDAI
- Single-centre
Main finding
As reported in the abstract
Odds ratio
3.08
95% CI 0.30–31.33
P = 0.34
Events by group
OBZvs RTX
OR 3.08 (95% CI 0.30–31.33); P = 0.34
Observational data: associations, not effects.
Further findings
LLDAS attainment
P = 0.049
B cell depletion rate · 12 months · trend
P = 0.08
Hospitalisation duration
shortened by 7 · P = 0.04
CD19+ B cells · 6 months
P = 0.01
Median
| Outcome | OBZ | RTX | P value |
|---|---|---|---|
| SLEDAI-2K score | 2 (IQR 1–2) | 4 (IQR 2–4.25) | P = 0.04 |
Deaths
- No deaths occurred
Safety
Safety profiles
- Comparable between groups, both well tolerated
Original publication
Comparison of obinutuzumab and rituximab for treating neuropsychiatric lupus: a retrospective case-control study. Lupus Sci Med. Published 4 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →